Biomarkers of clinical course in covid-19 patients with cardiovascular comorbidity

A new coronavirus infection (COVID-19) tends to have severe course in patients with cardiovascular disease, with routine laboratory tests predicting adverse outcomes in such patients. The results of studies of interplaying factors are contradictory and require further investigation. The aim was to analyze the parameters of general blood analysis, inflammatory response, cholesterol and hemostasis in the groups of patients who underwent COVID-19-associated pneumonia with cardiovascular comorbidity. The study was conducted in Veliky Novgorod from December 2020 to April 2022 during inpatient treatment of patients diagnosed with COVID-19-associated novel coronavirus infection. We analyzed 108 case histories of patients. The patient’s data was divided into 2 groups. Group I consisted of 86 patients with cardiovascular diseases at the time of admission. The control group consisted of 22 patients without concomitant cardiovascular diseases. The data of general blood analysis, biochemistry and hemostasis were assessed on the day of admission and on the day of discharge. Results. Average bed-days of patients with cardiovascular pathology were longer than in the control group; in addition, there was a correlation of the duration of hospitalization and CRP level with the initial level of total cholesterol. Also, positive correlation of CRP level with blood fibrinogen content was found, which was more expressed in patients with cardiovascular comorbidity. Conclusions. The results of our study, in general, do not contradict the results accumulated in the world. Those findings should be compared with other studies and to monitor COVID-19 disease trends.